Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), announces today that it has appointed an investment services provider to purchase 450,000 Ipsen SA shares, or about 0.54% of the share capital, over a maximum period of 6 months. The shares purchased under this agreement will be mainly a...
Data published evaluates fibrodysplasia ossificans progressiva (FOP) natural disease progression The Natural History Study (NHS) is the first protocol-specified, longitudinal evaluation of FOP disease progression Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), shared data from...
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005876/en/ David Loew, CEO at Ipsen as of July 1st 2020 (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its Board of Dire...
Over 400 patients with spasticity or cervical dystonia responded to online surveys evaluating the disease burden and the impact on their personal and professional lives Results reveal the need for longer-lasting symptoms control to improve patients’ perceived quality of life ...
First published comparative data for key second-line (2L) advanced hepatocellular carcinoma (aHCC) treatments using a matching-adjusted indirect comparison (MAIC) The MAIC shows that Cabometyx ® (cabozantinib) increased median progression-free survival by 80.6% (5.6 months vs....
Quick Take Lantern Pharma ( LTRN ) intends to raise $25 million in gross proceeds from an IPO of its common stock, per an amended registration statement . The company is advancing a pipeline of drug treatment candidates identified by its proprietary RADR platform. LTRN believes it can b...
Ipsen ( OTCPK:IPSEY ), IRICoR, a pan-Canadian research commercialization center and Université de Montréal, have entered into an option agreement by which Ipsen would acquire an exclusive license for the worldwide rights to a high-value oncology program. More news on: Ipsen S.A...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, IRICoR, a pan-Canadian research commercialization center focused on drug discovery, and Université de Montréal, today announced they entered into an option agreement by which Ips...
The frustrating reality for a lot of biotech shareholders is that while these stocks can enjoy strong runs on thesis-altering data announcements, a lot of time as a biotech investor is spent waiting. Such is the case for Lexicon Pharmaceuticals ( LXRX ) today. Whatever commercial sales poten...
Ipsen S.A. ( OTCPK:IPSEY ) Q1 results ((€)): More news on: Ipsen S.A., Ipsen S.A., Healthcare stocks news, Earnings news and commentary, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...